Selected research
Industry Research
Recombinant Vector Vaccines Industry Research Report 2026
Market perspective
The global Recombinant Vector Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Recombinant Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Recombinant Vector Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Recombinant Vector Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., CNBG, SINOVAC BIOTECH, Zhifei, GSK, Hualan Bio, ChengDa Bio, NuoCheng Bio and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Recombinant Vector Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Vector Vaccines Market by Company
SANOFI PASTEUR S.A.
CNBG
SINOVAC BIOTECH
Zhifei
GSK
Hualan Bio
ChengDa Bio
NuoCheng Bio
Novartis
Kangtai
Changsheng Life
Recombinant Vector Vaccines Segment by Type
Varicella
Influenza
Hepatitis
Pneumococcal
Pertussis, Diphtheria, tetanus
Others
Recombinant Vector Vaccines Segment by Application
For Adult
For Child
Recombinant Vector Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Vector Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Recombinant Vector Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Recombinant Vector Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Recombinant Vector Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Varicella
- Influenza
- Hepatitis
- Pneumococcal
- Pertussis, Diphtheria, tetanus
- Others
Applications
- For Adult
- For Child
Companies covered
- SANOFI PASTEUR S.A.
- CNBG
- SINOVAC BIOTECH
- Zhifei
- GSK
- Hualan Bio
- ChengDa Bio
- NuoCheng Bio
- Novartis
- Kangtai
- Changsheng Life
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Recombinant Vector Vaccines Market Size (2021-2032)
- 2.2.2 Global Recombinant Vector Vaccines Sales (2021-2032)
- 2.2.3 Global Recombinant Vector Vaccines Market Average Price (2021-2032)
- 2.3 Recombinant Vector Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Varicella
- 2.3.3 Influenza
- 2.3.4 Hepatitis
- 2.3.5 Pneumococcal
- 2.3.6 Pertussis, Diphtheria, tetanus
- 2.3.7 Others
- 2.4 Recombinant Vector Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 For Adult
- 2.4.3 For Child
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Recombinant Vector Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Recombinant Vector Vaccines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Recombinant Vector Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Recombinant Vector Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Recombinant Vector Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Recombinant Vector Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Recombinant Vector Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Recombinant Vector Vaccines, Established Date
- 3.9 Global Recombinant Vector Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 SANOFI PASTEUR S.A.
- 4.1.1 SANOFI PASTEUR S.A. Company Information
- 4.1.2 SANOFI PASTEUR S.A. Business Overview
- 4.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
- 4.1.5 SANOFI PASTEUR S.A. Recent Developments
- 4.2 CNBG
- 4.2.1 CNBG Company Information
- 4.2.2 CNBG Business Overview
- 4.2.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 CNBG Recombinant Vector Vaccines Product Portfolio
- 4.2.5 CNBG Recent Developments
- 4.3 SINOVAC BIOTECH
- 4.3.1 SINOVAC BIOTECH Company Information
- 4.3.2 SINOVAC BIOTECH Business Overview
- 4.3.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
- 4.3.5 SINOVAC BIOTECH Recent Developments
- 4.4 Zhifei
- 4.4.1 Zhifei Company Information
- 4.4.2 Zhifei Business Overview
- 4.4.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
- 4.4.5 Zhifei Recent Developments
- 4.5 GSK
- 4.5.1 GSK Company Information
- 4.5.2 GSK Business Overview
- 4.5.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 GSK Recombinant Vector Vaccines Product Portfolio
- 4.5.5 GSK Recent Developments
- 4.6 Hualan Bio
- 4.6.1 Hualan Bio Company Information
- 4.6.2 Hualan Bio Business Overview
- 4.6.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
- 4.6.5 Hualan Bio Recent Developments
- 4.7 ChengDa Bio
- 4.7.1 ChengDa Bio Company Information
- 4.7.2 ChengDa Bio Business Overview
- 4.7.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
- 4.7.5 ChengDa Bio Recent Developments
- 4.8 NuoCheng Bio
- 4.8.1 NuoCheng Bio Company Information
- 4.8.2 NuoCheng Bio Business Overview
- 4.8.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
- 4.8.5 NuoCheng Bio Recent Developments
- 4.9 Novartis
- 4.9.1 Novartis Company Information
- 4.9.2 Novartis Business Overview
- 4.9.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Novartis Recombinant Vector Vaccines Product Portfolio
- 4.9.5 Novartis Recent Developments
- 4.10 Kangtai
- 4.10.1 Kangtai Company Information
- 4.10.2 Kangtai Business Overview
- 4.10.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Kangtai Recombinant Vector Vaccines Product Portfolio
- 4.10.5 Kangtai Recent Developments
- 4.11 Changsheng Life
- 4.11.1 Changsheng Life Company Information
- 4.11.2 Changsheng Life Business Overview
- 4.11.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
- 4.11.5 Changsheng Life Recent Developments
5 Global Recombinant Vector Vaccines Market Scenario by Region
- 5.1 Global Recombinant Vector Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Recombinant Vector Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Recombinant Vector Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Recombinant Vector Vaccines Sales by Region: 2027-2032
- 5.3 Global Recombinant Vector Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Recombinant Vector Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Recombinant Vector Vaccines Revenue by Region: 2027-2032
- 5.4 North America Recombinant Vector Vaccines Market Facts & Figures by Country
- 5.4.1 North America Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Recombinant Vector Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Recombinant Vector Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Recombinant Vector Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Recombinant Vector Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Recombinant Vector Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Recombinant Vector Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Recombinant Vector Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Recombinant Vector Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Recombinant Vector Vaccines Market Facts & Figures by Country
- 5.7.1 South America Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Recombinant Vector Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Recombinant Vector Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Recombinant Vector Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Recombinant Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Recombinant Vector Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Recombinant Vector Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Recombinant Vector Vaccines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Recombinant Vector Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Recombinant Vector Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Recombinant Vector Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Recombinant Vector Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Recombinant Vector Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Recombinant Vector Vaccines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Recombinant Vector Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Recombinant Vector Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Recombinant Vector Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Recombinant Vector Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Recombinant Vector Vaccines Value Chain Analysis
- 8.1.1 Recombinant Vector Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Recombinant Vector Vaccines Production Mode & Process
- 8.2 Recombinant Vector Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Recombinant Vector Vaccines Distributors
- 8.2.3 Recombinant Vector Vaccines Customers
9 Global Recombinant Vector Vaccines Analyzing Market Dynamics
- 9.1 Recombinant Vector Vaccines Industry Trends
- 9.2 Recombinant Vector Vaccines Industry Drivers
- 9.3 Recombinant Vector Vaccines Industry Opportunities and Challenges
- 9.4 Recombinant Vector Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst